2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5508 Long-term efficacy and safety of flumatinib 600 mg and 400 mg for newly diagnosed chronic phase chronic myeloid leukemia: A phase 4 double-blind randomized dose-optimization trial

Weiming Li, PhD, Wei Yang2, Haiping Yang, MD3, Junmin Li4, Hongyan Tong5, Huangling Zhu, MD6, LI Meng7, Yanli Zhang, MD8, Zunmin Zhu, MD9, Na Xu10, Bingcheng LIU, MD11, Yaming Xi12, Qun He13, Zhongxing Jiang14, Qian Jiang Jr, MD15, Pengcheng He16, Lie Lin17, Zhenfang Liu, DO18, Sujun Gao19, Xiaohua Luo20, Ming Hou21, Xin Du, MD22, Ya-Qing Feng23, Hong Liu24, Xinbao Hao25, Hongmei Jing26, Feng Zhang27, Fei Li, MD, PhD28, Linlin Sun29, Yang Yu30, Rili Jiang31, Jin Zhao32, Xiaoqing Zhang33, Jun Ma, MD34
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 472000,China, Wuhan, China
2 Shengjing Hospital of China Medical University, Shenyang, China
3 The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China
4 Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine, Shanghai, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Hangzhou, China
6 West China Hospital of Sichuan University, Chengdu, China
7 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
8 Henan Cancer Hospital, Zhengzhou, China, Zhengzhou, China
9 Henan Provincial People's Hospital, Zhengzhou, China, Zhengzhou, China
10 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
11 National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
12 The First Hospital of Lanzhou University, Lanzhou, China, Lanzhou, China
13 Xiangya Hospital, Central South University, Changsha, China, Changsha, China
14 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
15 Peking University Aerospace Clinical Medical College, Beijing, China
16 The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
17 Hainan Provincial People’s Hospital, Haikou, China
18 Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
19 The First Hospital of Jilin University-Hematology, Changchun, China
20 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, Chongqing, China
21 Department of Hematology,Qilu Hospital of Shandong University, Jinan, China
22 Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
23 Department of Hematology, The Third People's Hospital Of Datong, Datong, China, Datong, China
24 Affiliated Hospital of Nantong University, Nantong, China
25 The First Affiliated Hospital of Hainan Medical University, Haikou, China, Haikou, China
26 Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing, China
27 The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
28 First Affiliated Hospital of Nanchang University, Nanchang, China
29 Shanghai Hansoh Biomedical Co., Ltd, Shanghai, China
30 Shanghai Hansoh Biomedical Co., Ltd, Shanghai, China
31 Shanghai Hansoh Biomedical Co., Ltd, Shanghai, China
32 Shanghai Hansoh Biomedical Co., Ltd, Shanghai, China
33 Shanghai Hansoh Biomedical Co., Ltd, Shanghai, China
34 Harbin Institute of Hematology & Oncology, Harbin the First Hospital, Harbin, China

Background

Flumatinib is a second-generation tyrosine kinase inhibitor (TKI) independently developed in China. The phase 3 FESTnd trial (CTR20140513) evaluated flumatinib vs. imatinib in patients with newly diagnosed Chronic Phase Chronic Myeloid Leukemia (CML-CP), demonstrating the superiority of flumatinib 600 mg once daily (QD) and supporting its approval as first-line treatment for CML-CP. However, the balance between sustained long-term efficacy and tolerability highlights the need for further dose optimization. This phase 4 study (CTR20212881) was designed to evaluate the long-term efficacy and safety of flumatinib at dosages of 600 mg and 400 mg QD in newly diagnosed CML-CP Chinese patients, aiming to support the clinical practice of flumatinib used in CML-CP patients.

 

Methods

This was a multicenter, randomized, double-blind phase 4 trial conducted in 35 centers in China, with a planned enrollment of 200 patients. Eligible patients were randomized 1:1 to receive flumatinib 600 mg or 400 mg once daily in 28-day cycles. The primary endpoint was the rate of early molecular response (EMR) at 3 months.

 

Results

From November 23, 2021, to August 8, 2025, a total of 271 patients with newly diagnosed CML-CP were screened and 209 patients were randomly assigned to flumatinib 600 mg arm (n=103) QD or 400 mg QD arm (n=106). The median follow-up time was 33.8 months. The baseline characteristics were well balanced: median age, 48.0 (range:18-73) vs. 47.5 (range:19-74) years; EUTOS long-term survival (ELTS) score: low-risk 68 (66.0%) vs. 69 (65.1%); intermedium-risk 28 (27.2%) vs. 31 (29.2%); high-risk 7 (6.8%) vs. 6 (5.7%); Eastern Cooperative Oncology Group (ECOG) performance status 0: 77 (74.8%) vs. 85 (80.2%); ECOG 1: 26 (25.2%) vs. 21 (19.8%).

The 3-month EMR rate reached 81.6% (95% confidence interval [CI], 72.7%-88.5%) in 600 mg arm vs. 78.3% (95% CI, 69.2%-85.7%) in the 400 mg arm. The 12-month major molecular response (MMR) rates were 70.9% (95% CI, 61.1%-79.4%) vs. 67.0% (95% CI, 57.2%-75.8%), and the 24-month MMR rate was 72.8% (95% CI, 63.2%-81.1%) vs. 68.9% (95% CI, 59.1%-77.5%). The 12-month molecular response 4.0 (MR4.0) rate was 50.5% (95% CI, 40.5%-60.5%) in the 600 mg arm and 45.3% (95% CI, 35.6%-55.2%) in the 400 mg arm; corresponding 24-month rates were 48.5% (95% CI, 38.6%-58.6%) and 45.3% (95% CI, 35.6%-55.2%), respectively. The median time to MMR was 24.0 weeks in the 600 mg arm and 24.1 weeks in the 400 mg arm.

Subgroup analyses showed the MMR rate differed between two arms by age and ELTS score stratification. In patients aged ≤60 years, MMR rates at 12 months were 71.1% (95% CI, 60.1%- 80.5%) in the 600 mg arm and 62.5% (95% CI, 51.5%- 72.6%) in the 400 mg arm; at 24 months, MMR rates increased to 73.5% (95% CI, 62.7%-82.6%) and 65.9% (95% CI, 55.0%-75.7%), in 600 mg and 400 mg arm, respectively. For patients with intermediate or high risk ELTS scores, MMR rates at 12 months and 24 months were 60.0%(95% CI, 42.1%-76.1%) vs. 51.4%(95% CI, 34.4%-68.1%), and 65.7%(95% CI, 47.8%-80.9%) vs. 54.1%(95% CI, 36.9%-70.5%) in 600 mg and 400 mg arms, respectively, showing the gap in MMR rates between two arms increased as treatment duration extended.

Treatment-emergent adverse events (TEAEs) leading to dose interruption was observed in 26.5% of patients in the 600 mg arm and 33.0% in the 400 mg arm. TEAEs leading to dose reductions occurred in 8.8% patients in 600 mg arm and 11.3% in 400 mg arm, respectively. The most frequent ≥ grade 3 TEAEs (≥ 5%) were thrombocytopenia (17.6% vs. 17.9%), neutropenia (7.8% vs. 14.2%), and liver enzymes increased (5.9% vs.0.9%). In the 600 mg arm, ≥ grade 3 renal impairment occurred in 1.0% of patients, while no cases were reported in the 400 mg arm. No additional unexpected adverse events were observed.

 

Conclusions

Overall, both the 600 mg and 400 mg flumatinib doses demonstrated favorable outcomes in EMR and MMR, with the 600 mg dose exhibiting numerically higher rates of EMR, MMR, and MR4.0 compared to the 400 mg dose. Notably, the 600 mg arm yielded earlier and more profound molecular responses, especially in patients aged ≤60 years and those with intermediate or high risk ELTS scores, who had deeper and more sustained molecular responses. The incidence of adverse events was similar in both arms and no unexpected or untreatable adverse events occurred.

Jun Ma, MD: No relevant conflicts of interest to declare.